908 Devices Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kevin J. Knopp
- Full Time Employees
- 246
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 645 Summer Street Boston MA United States of America 02210
- IPO Date
- Dec 18, 2020
- CIK
- 0001555279
- Website
- 908devices.com
- Similar Companies
- Business
- 908 Devices Inc. (Nasdaq: MASS) develops and commercializes purpose-built handheld chemical analysis devices leveraging mass spectrometry, microfluidic separations, and optical spectroscopy technologies for point-of-need detection and identification of hazardous substances in vital health, safety, and defense applications. The company offers MX908, a handheld mass spectrometer for trace-level analysis of solids, liquids, vapors, and aerosols including narcotics, explosives, precursors, and chemical threats; VipIR and XplorIR, portable analyzers combining FTIR and Raman spectroscopy with smart spectral processing for bulk solid/liquid identification and gas/vapor quantification at ppm levels; MX908 Beacon for enhanced area monitoring; and robotic-integrated gas detectors, serving customs and borders, hazmat/CBRN response, EOD, narcotics enforcement, and industrial monitoring markets. 908 Devices operates in the United States, Europe, the Middle East, Africa, Asia Pacific, and other regions. Founded in 2012 and headquartered at 645 Summer Street in Boston, Massachusetts, the company went public in 2020. In March 2025, Repligen Corporation acquired 908 Devices' bioprocessing analytics portfolio, including desktop devices Rebel, Maverick, Maven, and related accessories for real-time bioprocess monitoring of glucose, lactate, biomass, and media analysis, allowing 908 Devices to concentrate on handheld platforms for chemical detection; in 2024, it acquired RedWave Technology, integrating portable FTIR analyzers to expand forensics offerings and bolster optical capabilities for first responders.
908 Devices Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
908 Devices to Present at the 16th Annual East Coast IDEAS Investor Conference
908 Devices Looking Better Now (Rating Upgrade)
908 Devices Inc. (MASS) Q1 2026 Earnings Call Transcript
908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook
908 Devices Acquires NIRLAB AG, Expanding Its Narcotics Detection Portfolio
908 Devices to Report First Quarter 2026 Financial Results on May 6, 2026
908 Devices Appoints Kola Otitoju as Chief Business & Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Masivo Silver Extends and Completes First Hole at Cerro Colorado Project
908 Devices to Present at the Sidoti Small Cap Conference
'MASS DOMESTIC SURVEILLANCE': Anthropic comes under Pentagon fire, official warns of 'spying'
Short Interest in 908 Devices Inc. (NASDAQ:MASS) Rises By 20.0%
908 Devices Q4 Earnings Call Highlights
908 Devices Inc. (MASS) Q4 2025 Earnings Call Transcript
908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates
908 Devices Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Revenue Outlook
Masivo Silver Corp. Launches Phase I Drill Program at Cerro Colorado Project, Sonora, Mexico
908 Devices to Participate in Investor Conferences in March
908 Devices to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026